<DOC>
	<DOCNO>NCT01592396</DOCNO>
	<brief_summary>The pharmacokinetic ( PK ) profile tralokinumab ( CAT‐354 ) study adolescent subject asthma .</brief_summary>
	<brief_title>A Phase 1 , Open-label Study Investigate Pharmacokinetics Tralokinumab ( CAT-354 ) Adolescents With Asthma</brief_title>
	<detailed_description>Interleukin-13 ( IL‐13 ) pleiotropic cytokine promotes inflammation , airways hyper‐responsiveness ( directly recruitment activation inflammatory cell ) , mucus hypersecretion , airway remodel via fibrosis , increase immunoglobulin E ( IgE ) synthesis mast cell activation.Tralokinumab ( CAT‐354 ) human immunoglobulin G4 ( IgG4 ) anti‐IL‐13 monoclonal antibody show potently specifically neutralize IL‐13 preclinical models.This study evaluate PK profile single dose tralokinumab administer subcutaneously dose 300 mg adolescent subject asthma compare PK data complete study adult .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Age 1217 year ( inclusive ) Weight great ( &gt; ) 30 kilogram ( kg ) Asthma minimum 6 month prior Screening Effective birth control male female participant line protocol detail . Previously take tralokinumab ( study drug ) Employee clinical study site individual directly involve conduct study , immediate family member individual Pregnant breastfeed woman Current smoker cessation le ( &lt; ) 3 month prior screen Known immune deficiency exclude asymptomatic selective immunoglobulin A History cancer Hepatitis B , C human immunodeficiency virus ( HIV ) positive Any disease may cause complication whilst take study drug .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Tralokinumab</keyword>
	<keyword>CAT-354</keyword>
	<keyword>Asthma</keyword>
</DOC>